Top Midday Decliners

MT Newswires Live2025-03-01

Praxis Precision Medicines (PRAX) said Friday it received a recommendation from an independent data monitoring committee overseeing its study 1 of the so-called Essential3 program of ulixacaltamide in essential tremor that the trial be "stopped for futility."

Truist Securities adjusted Praxis's share-price target to $85 from $175 while maintaining its buy rating.

Shares of Praxis slumped 39% following a surge in intraday trading volume to over 2.1 million from a daily average of about 363,000.

DoubleVerify (DV) reported a surprise drop late Thursday in Q4 net income, and its guidance range for Q1 sales also missed market expectations.

Goldman Sachs downgraded the company's shares to neutral from buy, with a $20 price target.

Shares of DoubleVerify sank 36%, with intraday trading volume catapulting to over 10 million versus a daily average of about 1.5 million.

NetApp (NTAP) "unexpectedly stumbled" in fiscal Q3 with revenue at the low end of guidance, and Q4 rebound expectations "muted," Wedbush Securities said Friday in a review of NetApp's earnings overnight.

Wells Fargo adjusted NetApp's share-price target to $115 from $130 while keeping its equal-weight rating.

Shares of NetApp retreated 17% as intraday trading volume surged to more than 5.5 million from a daily average of roughly 1.6 million.

Price: 39.70, Change: -25.33, Percent Change: -38.95

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2516796308?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-01 03:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516796308","market":"sg","top_or_hot":-1,"title":"Top Midday Decliners","media":"MT Newswires Live","content":"<html><body><p> Praxis Precision Medicines (PRAX) said Friday it received a recommendation from an independent data monitoring committee overseeing its study 1 of the so-called Essential3 program of ulixacaltamide in essential tremor that the trial be \"stopped for futility.\"</p><p>Truist Securities adjusted Praxis's share-price target to $85 from $175 while maintaining its buy rating.</p><p>Shares of Praxis slumped 39% following a surge in intraday trading volume to over 2.1 million from a daily average of about 363,000.</p><p>DoubleVerify (DV) reported a surprise drop late Thursday in Q4 net income, and its guidance range for Q1 sales also missed market expectations.</p><p>Goldman Sachs downgraded the company's shares to neutral from buy, with a $20 price target.</p><p>Shares of DoubleVerify sank 36%, with intraday trading volume catapulting to over 10 million versus a daily average of about 1.5 million.</p><p>NetApp (NTAP) \"unexpectedly stumbled\" in fiscal Q3 with revenue at the low end of guidance, and Q4 rebound expectations \"muted,\" Wedbush Securities said Friday in a review of NetApp's earnings overnight.</p><p>Wells Fargo adjusted NetApp's share-price target to $115 from $130 while keeping its equal-weight rating.</p><p>Shares of NetApp retreated 17% as intraday trading volume surged to more than 5.5 million from a daily average of roughly 1.6 million.</p><p>Price: 39.70, Change: -25.33, Percent Change: -38.95</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Midday Decliners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Midday Decliners\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-01 03:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Praxis Precision Medicines (PRAX) said Friday it received a recommendation from an independent data monitoring committee overseeing its study 1 of the so-called Essential3 program of ulixacaltamide in essential tremor that the trial be \"stopped for futility.\"</p><p>Truist Securities adjusted Praxis's share-price target to $85 from $175 while maintaining its buy rating.</p><p>Shares of Praxis slumped 39% following a surge in intraday trading volume to over 2.1 million from a daily average of about 363,000.</p><p>DoubleVerify (DV) reported a surprise drop late Thursday in Q4 net income, and its guidance range for Q1 sales also missed market expectations.</p><p>Goldman Sachs downgraded the company's shares to neutral from buy, with a $20 price target.</p><p>Shares of DoubleVerify sank 36%, with intraday trading volume catapulting to over 10 million versus a daily average of about 1.5 million.</p><p>NetApp (NTAP) \"unexpectedly stumbled\" in fiscal Q3 with revenue at the low end of guidance, and Q4 rebound expectations \"muted,\" Wedbush Securities said Friday in a review of NetApp's earnings overnight.</p><p>Wells Fargo adjusted NetApp's share-price target to $115 from $130 while keeping its equal-weight rating.</p><p>Shares of NetApp retreated 17% as intraday trading volume surged to more than 5.5 million from a daily average of roughly 1.6 million.</p><p>Price: 39.70, Change: -25.33, Percent Change: -38.95</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTAP","symbol_name":"美国网存","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2516796308","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516796308","pubTimestamp":1740769443,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Praxis Precision Medicines (PRAX) said Friday it received a recommendation from an independent data monitoring committee overseeing its study 1 of the so-called Essential3 program of ulixacaltamide in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTAP":"美国网存","BK4170":"电脑硬件、储存设备及电脑周边","BK4539":"次新股","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4023":"应用软件","PRAX":"Praxis Precision Medicines, Inc.","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","BK4139":"生物科技","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","DV":"DoubleVerify Holdings, Inc."},"translate_title":"午盘跌幅最大的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTAP":0.9,"DV":0.9,"PRAX":0.9},"content_text":"Praxis Precision Medicines (PRAX) said Friday it received a recommendation from an independent data monitoring committee overseeing its study 1 of the so-called Essential3 program of ulixacaltamide in essential tremor that the trial be \"stopped for futility.\"Truist Securities adjusted Praxis's share-price target to $85 from $175 while maintaining its buy rating.Shares of Praxis slumped 39% following a surge in intraday trading volume to over 2.1 million from a daily average of about 363,000.DoubleVerify (DV) reported a surprise drop late Thursday in Q4 net income, and its guidance range for Q1 sales also missed market expectations.Goldman Sachs downgraded the company's shares to neutral from buy, with a $20 price target.Shares of DoubleVerify sank 36%, with intraday trading volume catapulting to over 10 million versus a daily average of about 1.5 million.NetApp (NTAP) \"unexpectedly stumbled\" in fiscal Q3 with revenue at the low end of guidance, and Q4 rebound expectations \"muted,\" Wedbush Securities said Friday in a review of NetApp's earnings overnight.Wells Fargo adjusted NetApp's share-price target to $115 from $130 while keeping its equal-weight rating.Shares of NetApp retreated 17% as intraday trading volume surged to more than 5.5 million from a daily average of roughly 1.6 million.Price: 39.70, Change: -25.33, Percent Change: -38.95","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2516796308","isCrawlerRequest":true}